Traws Pharma, Inc. (TRAW)
NASDAQ: TRAW · Real-Time Price · USD
2.240
-0.160 (-6.67%)
Mar 31, 2025, 3:33 PM EDT - Market open
Traws Pharma Revenue
Traws Pharma had revenue of $57.00K in the quarter ending September 30, 2024. This brings the company's revenue in the last twelve months to $226.00K. In the year 2023, Traws Pharma had annual revenue of $226.00K.
Revenue (ttm)
$226.00K
Revenue Growth
n/a
P/S Ratio
10.54
Revenue / Employee
$12,556
Employees
18
Market Cap
8.18M
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2023 | 226.00K | - | - |
| Dec 31, 2022 | 226.00K | - | - |
| Dec 31, 2021 | 226.00K | -5.00K | -2.16% |
| Dec 31, 2020 | 231.00K | -1.95M | -89.42% |
| Dec 31, 2019 | 2.18M | 955.00K | 77.77% |
| Dec 31, 2018 | Pro | Pro | Pro |
| Dec 31, 2017 | Pro | Pro | Pro |
| Dec 31, 2016 | Pro | Pro | Pro |
| Dec 31, 2015 | Pro | Pro | Pro |
| Dec 31, 2014 | Pro | Pro | Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| UnitedHealth Group | 400.28B |
| Johnson & Johnson | 88.82B |
| Merck & Co. | 64.17B |
| AbbVie | 56.33B |
| AstraZeneca | 54.07B |
| Novartis AG | 51.72B |
| Eli Lilly and Company | 45.04B |
| Thermo Fisher Scientific | 42.88B |
TRAW News
- 2 days ago - Traws Pharma Announces Management Updates - GlobeNewsWire
- 5 days ago - Traws Pharma to Host Investor Event on Bird Flu and COVID Product Candidates Virtual Event to be Held on Monday, March 31, 2025 at 10:00 AM ET - GlobeNewsWire
- 6 days ago - Traws Pharma's COVID-19 Candidate, Ratutrelvir, Presented at ICAR - GlobeNewsWire
- 10 days ago - Traws Pharma's Bird Flu Drug Candidate, Tivoxavir Marboxil, Presented at ICAR - GlobeNewsWire
- 4 weeks ago - Traws Pharma Reports Positive Results from An Accepted Bird Flu Model for Anti-Viral Candidate, Tivoxavir Marboxil - GlobeNewsWire
- 4 weeks ago - Traws Pharma Regains Compliance with NASDAQ Equity Listing Rule - GlobeNewsWire
- 2 months ago - Traws Pharma Announces Completion of Phase I Studies with Tivoxavir Marboxil, a Single Dose Oral Investigational Drug for the Treatment and Prevention of H5N1 Bird Flu - PRNewsWire
- 2 months ago - Expert Systems and Traws Pharma Report Breakthrough in H5N1Bird Flu Antiviral Program - PRNewsWire